Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romiplostim with intensified immunosuppression for severe aplastic anemia
ChiCTR2600121288Phase 2Not yet recruiting
- Sponsor
- Jiangsu Provincial People's Hospital
- Start
- Mar 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of romiplostim in aplastic anemia, sponsored by Jiangsu Provincial People's Hospital. Primary endpoint: 3-month complete response rate. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
romiplostim
03
Conditions
aplastic anemia
Beyond the preview
Go deeper on ChiCTR2600121288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600121288.